An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Deutetrabenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RIM-TD
- Sponsors Auspex Pharmaceuticals
Most Recent Events
- 23 Sep 2024 According to a Teva Pharmaceuticals media release, data were presented at the European College of Neuropsychopharmacology Congress (ECNP) in Milan 21-24 September 2024.
- 23 Sep 2024 Results of new analysis from the European cohort of the RIM-TD open-label extension (OLE) study presented in a Teva Pharmaceuticals media release.
- 10 Jun 2022 Results of a post hoc analysis of OLE study assessed long-term efficacy and safety of DTBZ in postmenopausal women presented at the 175th Annual Meeting of the American Psychiatric Association